Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models
Open accessThe DOI matches its Crossref record; 48 of the 50 references it cites were found in a registry or an index.
Abstract
Bacteria can be genetically engineered to kill specific pathogens or inhibit their virulence. We previously developed a synthetic genetic system that allows a laboratory strain of Escherichia coli to sense and kill Pseudomonas aeruginosa in vitro . Here, we generate a modified version of the system, including a gene encoding an anti-biofilm enzyme, and use the probiotic strain Escherichia coli Nissle 1917 as host. The engineered probiotic shows in vivo prophylactic and therapeutic activity against P. aeruginosa during gut infection in two animal models ( Caenorhabditis elegans and mice). These findings support the further development of engineered microorganisms with potential prophylactic and therapeutic activities against gut infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“For example, Hwang et. al. demonstrated that the EcN-based gastrointestinal delivery of anti-biofilm enzyme, dispersin B (DspB), resulted in a reduction of pre-colonized P. aeruginosa abundance in both nematode and murine models29.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [29]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Regulating effector expression in response to bacterial quorum sensing molecules29, pH30, specific carbon sources31–33, temperature34, or combinations of these signals may allow for exquisitely tuned effector functions in various intestinal microenvironments7.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products
Datsenko, K. A., & Wanner, B. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120163297 · Cited by 14,782
The Involvement of Cell-to-Cell Signals in the Development of a Bacterial Biofilm
Davies, D. G., Parsek, M. R., Pearson, J. P., Iglewski, B. H., Costerton, J. W., & Greenberg, E. P. (1998) · Science · doi:10.1126/science.280.5361.295 · Cited by 3,396
Ceri, H., Olson, M. E., Stremick, C., Read, R. R., Morck, D., & Buret, A. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.6.1771-1776.1999 · Cited by 2,155
Interdependence of Cell Growth and Gene Expression: Origins and Consequences
Scott, M., Gunderson, C. W., Mateescu, E. M., Zhang, Z., & Hwa, T. (2010) · Science · doi:10.1126/science.1192588 · Cited by 1,470
Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients
Smith, E. E., Buckley, D. G., Wu, Z., Saenphimmachak, C., Hoffman, L. R., D’Argenio, D. A., Miller, S. I., Ramsey, B. W., Speert, D. P., Moskowitz, S. M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602138103 · Cited by 1,319
Tan, M.-W., Mahajan-Miklos, S., & Ausubel, F. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.2.715 · Cited by 1,002
Synchronized cycles of bacterial lysis for in vivo delivery
Din, M. O., Danino, T., Prindle, A., Skalak, M., Selimkhanov, J., Allen, K., Julio, E., Atolia, E., Tsimring, L. S., Bhatia, S. N., et al. (2016) · Nature · doi:10.1038/nature18930 · Cited by 784
Refinement and standardization of synthetic biological parts and devices
Canton, B., Labno, A., & Endy, D. (2008) · Nature Biotechnology · doi:10.1038/nbt1413 · Cited by 753
The gastrointestinal tract. The “undrained abscess” of multiple organ failure
Marshall, J. C., Christou, N. V., & Meakins, J. L. (1993) · Annals of Surgery · doi:10.1097/00000658-199308000-00001 · Cited by 707
de Jonge, E., Schultz, M. J., Spanjaard, L., Bossuyt, P. M., Vroom, M. B., Dankert, J., & Kesecioglu, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14409-1 · Cited by 587
Cited by
Items 101–200 of 481
Integrating Systems and Synthetic Biology to Understand and Engineer Microbiomes
Leggieri, P. A., Liu, Y., Hayes, M. M., Connors, B., Seppälä, S., O’Malley, M., & Venturelli, O. S. (2021) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-082120-022836 · Cited by 76
Targeted Approaches for In Situ Gut Microbiome Manipulation
Lee, H. L., Shen, H., Hwang, I. Y., Ling, H., Yew, W. S., Lee, Y. S., & Chang, M. W. (2018) · Genes · doi:10.3390/genes9070351 · Cited by 71
“For example, an improved ‘sense-kill’ system [63] employed in EcN was shown to successfully eradicate and prevent Pseudomonas aeruginosa colonisation in both Caenorhabditis elegans and murine models [64].”
BackgroundSelf-citationGenetically Engineered Microorganisms and Their Impact on Human Health
Mahdizade Ari, M., Dadgar, L., Elahi, Z., Ghanavati, R., & Taheri, B. (2024) · International Journal of Clinical Practice · doi:10.1155/2024/6638269 · Cited by 67
“To increase genetic stability, most GMOs carry recombinant DNA in their chromosomes because plasmids are not genetically stable due to unequal distribution between daughter cells during cell division; also, they are lost in the absence of selective pressure [109, 120, 196, 302].”
BackgroundIntestinal microbiome as a risk factor for urinary tract infections in children
Paalanne, N., Husso, A., Salo, J., Pieviläinen, O., Tejesvi, M. V., Koivusaari, P., Pirttilä, A. M., Pokka, T. M.-L., Mattila, S., Jyrkäs, J., et al. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3322-7 · Cited by 68
Controlling biofilms using synthetic biology approaches
Fang, K., Park, O.-J., & Hong, S. H. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107518 · Cited by 71
“Tools employing synthetic biology approaches are also used to investigate the organization of biofilms, uncover the mechanisms of actions of antibiofilm agents and design strategies to combat biofilms (Brenner and Arnold, 2011; Hong et al., 2012; Hwang et al., 2017).”
BackgroundGenetic Circuit-Assisted Smart Microbial Engineering
Gao, C., Xu, P., Ye, C., Chen, X., & Liu, L. (2019) · Trends in Microbiology · doi:10.1016/j.tim.2019.07.005 · Cited by 65
Zhu, Y., You, Y., Chen, Z., Xu, D., Yue, W., Ma, X., Jiang, J., Wu, W., Lin, H., & Shi, J. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c00118 · Cited by 67
McKay, R., Ghodasra, M., Schardt, J. S., Quan, D. N., Pottash, A. E., Shang, W., Jay, S. M., Payne, G. F., Chang, M. W., March, J. C., et al. (2018) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10113 · Cited by 66
Self-citationBiosensing in Smart Engineered Probiotics
Rottinghaus, A. G., Amrofell, M. B., & Moon, T. S. (2020) · Biotechnology Journal · doi:10.1002/biot.201900319 · Cited by 66
Genetic Engineering of Resident Bacteria in the Gut Microbiome
Arnold, J. H., Glazier, J., & Mimee, M. (2023) · Journal of Bacteriology · doi:10.1128/jb.00127-23 · Cited by 67
Designer cells programming quorum-sensing interference with microbes
Sedlmayer, F., Hell, D., Müller, M., Ausländer, D., & Fussenegger, M. (2018) · Nature Communications · doi:10.1038/s41467-018-04223-7 · Cited by 69
Living fabrication of functional semi-interpenetrating polymeric materials
Dai, Z., Yang, X., Wu, F., Wang, L., Xiang, K., Li, P., Lv, Q., Tang, J., Dohlman, A. B., Dai, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23812-7 · Cited by 66
Li, J., Sun, M., Liu, L., Yang, W., Sun, A., Yu, J., Liu, D., Zhao, W., Cheng, M., He, Z., et al. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c02408 · Cited by 64
Synthetic Biology and the Gut Microbiome
Dou, J., & Bennett, M. R. (2017) · Biotechnology Journal · doi:10.1002/biot.201700159 · Cited by 63
“elegans and murine gut model [105], and this model of targeted delivery, modified thoughtfully according to the”
Bacterial biofilms as platforms engineered for diverse applications
Li, Z., Wang, X., Wang, J., Yuan, X., Jiang, X., Wang, Y., Zhong, C., Xu, D., Gu, T., & Wang, F. (2022) · Biotechnology Advances · doi:10.1016/j.biotechadv.2022.107932 · Cited by 67
O’Mahony, A. K., Álvarez‐Ordóñez, A., Filloux, A., Gahan, C. G. M., & Cotter, P. D. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1002185 · Cited by 70
Tannic acid-based metal-phenolic networks as a versatile platform to mediate cell therapy
Luo, H., Xie, J., Su, X., Wang, P., Chen, H., Kuang, X., & Liu, J. (2024) · Science China Materials · doi:10.1007/s40843-024-3139-3 · Cited by 59
“As a natural poly-phenolic compound, TA is rich in aromatic rings and hydroxyl groups, exhibiting excellent chelating ability, forming stable coordination bonds with metal ions, and constructing a metal-phenolic complex with unique properties and functions [25,26].”
Synthetic Biology Approaches in the Development of Engineered Therapeutic Microbes
Kang, M., Choe, D., Kim, K., Cho, B., & Cho, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228744 · Cited by 64
Engineered Living Materials Based on Adhesin-Mediated Trapping of Programmable Cells
Guo, S., Dubuc, E., Rave, Y., Verhagen, M., Twisk, S. A. E., van der Hek, T., Oerlemans, G. J. M., van den Oetelaar, M. C. M., van Hazendonk, L. S., Brüls, M., et al. (2020) · ACS Synthetic Biology · doi:10.1021/acssynbio.9b00404 · Cited by 57
Liu, M., Feng, P., Kakade, A., Yang, L., Chen, G., Yan, X., Ni, H., Liu, P., Kulshrestha, S., Abomohra, A., et al. (2020) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2020.122032 · Cited by 55
A Universal and Ultrastable Mineralization Coating Bioinspired from Biofilms
Yang, X., Li, Z., Xiao, H., Wang, N., Li, Y., Xu, X., Chen, Z., Tan, H. S., & Li, J. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201802730 · Cited by 56
Chappell, T. C., & Nair, N. U. (2020) · npj Biofilms and Microbiomes · doi:10.1038/s41522-020-00156-6 · Cited by 55
Quantifying and Engineering Mucus Adhesion of Probiotics
Mays, Z. J. S., Chappell, T. C., & Nair, N. U. (2020) · ACS Synthetic Biology · doi:10.1021/acssynbio.9b00356 · Cited by 62
Bioactive peptides produced by engineered probiotics and other food-grade bacteria: A review
Romero‐Luna, H. E., Hernández‐Mendoza, A., González-Córdova, A. F., & Peredo-Lovillo, A. G. (2021) · Food Chemistry X · doi:10.1016/j.fochx.2021.100196 · Cited by 68
Engineered bacteria as drug delivery vehicles: Principles and prospects
Zhou, Y., & Han, Y. C. (2022) · Engineering Microbiology · doi:10.1016/j.engmic.2022.100034 · Cited by 56
Probiotic engineering strategies for the heterologous production of antimicrobial peptides
Mejía-Pitta, A., Broset, E., & de la Fuente‐Núñez, C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113863 · Cited by 58
Engineered live bacteria as disease detection and diagnosis tools
Tanniche, I., & Behkam, B. (2023) · Journal of Biological Engineering · doi:10.1186/s13036-023-00379-z · Cited by 65
de Barros, P. P., Scorzoni, L., Ribeiro, F. D. C., Fugisaki, L. R. D. O., Fuchs, B. B., Mylonakis, E. E., Jorge, A. O. C., Junqueira, J. C., & Rossoni, R. D. (2018) · Microbial Pathogenesis · doi:10.1016/j.micpath.2018.02.019 · Cited by 60
Combining omics technologies with CRISPR-based genome editing to study food microbes
Pan, M., & Barrangou, R. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.12.027 · Cited by 57
Streptococcus thermophilus Attenuates Inflammation in Septic Mice Mediated by Gut Microbiota
Han, F., Wu, G., Zhang, Y., Zheng, H., Han, S., Li, X., Cai, W., Liu, J., Zhang, W., Zhang, X., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.598010 · Cited by 53
“Furthermore, probiotics can alleviate inflammation associated with some human diseases by regulating the gut microbiota composition (Hwang et al., 2017; Wu et al., 2017).”
Native and Engineered Probiotics: Promising Agents against Related Systemic and Intestinal Diseases
Shen, H., Zhao, Z., Zhao, Z., Chen, Y., & Zhang, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020594 · Cited by 58
Huang, Y., Xiaojun, L., Yu, S., Chen, R., & Chen, W.-Z. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.2c00314 · Cited by 59
Sadhu, S., Paul, T., & Yadav, N. (2025) · Archives of Microbiology · doi:10.1007/s00203-025-04417-w · Cited by 63
“Hwang et al. ( 2017 ) provided a notable example by altering E. coli Nissle to specifically target Pseudomonas aeruginosa , an opportunistic pathogen that may proliferate in the gut after antibiotic therapy.”
Naydich, A. D., Nangle, S. N., Bues, J., Trivedi, D., Nissar, N., Inniss, M. C., Niederhuber, M. J., Way, J. C., Silver, P. A., & Riglar, D. T. (2019) · mSystems · doi:10.1128/msystems.00125-19 · Cited by 51
“To this end, recent in vivo approaches have developed sensors responding to inflammation (3, 4), intestinal bleeding (5), and pathogen quorum-sensing systems (6, 7).”
BackgroundEfficient engineered probiotics using synthetic biology approaches: A review
Yadav, M., & Shukla, P. (2019) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1822 · Cited by 56
Quorum Sensing System Used as a Tool in Metabolic Engineering
Ge, C., Sheng, H., Chen, X., Shen, X., Sun, X., Yan, Y., Wang, J., & Yuan, Q. (2020) · Biotechnology Journal · doi:10.1002/biot.201900360 · Cited by 50
The Strategies of Pathogen-Oriented Therapy on Circumventing Antimicrobial Resistance
Shang, Z., Chan, S. Y., Song, Q., Li, P., & Huang, W. (2020) · Research · doi:10.34133/2020/2016201 · Cited by 51
“Engineered probiotics represent a more primitive way to combat against AMR and have shown great potential in preventive and therapeutic activity against intestinal infections [264].”
BackgroundEngineering a genome‐reduced bacterium to eliminate Staphylococcus aureus biofilms in vivo
Garrido, V., Piñero‐Lambea, C., Rodríguez-Arce, I., Paetzold, B., Ferrar, T. S., Weber, M. L., García-Ramallo, E., Gallo, C., Collantes, M., Peñuelas, I., et al. (2021) · Molecular Systems Biology · doi:10.15252/msb.202010145 · Cited by 49
“Only an engineered E. coli Nissle strain has been specifically designed to destroy P. aeruginosa biofilms, producing remarkable results in the gastrointestinal tract of a murine model (Hwang et al, 2017).”
BackgroundBeyond the Green Fluorescent Protein: Biomolecular Reporters for Anaerobic and Deep-Tissue Imaging
Ozbakir, H. F., Anderson, N. T., Fan, K., & Mukherjee, A. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00688 · Cited by 51
Using Engineered Bacteria to Characterize Infection Dynamics and Antibiotic Effects In Vivo
Certain, L., Way, J. C., Pezone, M. J., & Collins, J. J. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.08.001 · Cited by 46
“Much work in synthetic biology to date has focused on engineering diagnostic or therapeutic devices (Braff et al., 2016; Daeffler et al., 2017; Danino et al., 2015; Hwang et al., 2017; Kojima et al., 2016; Riglar et al., 2017; Slomovic et al., 2015).”
BackgroundMa, T., Gan, G., Cheng, J. G., Shen, Z., Zhang, G., Liu, S., & Hu, J. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202502588 · Cited by 57
Systems and synthetic biology-driven engineering of live bacterial therapeutics
Kim, K., Kang, M., & Cho, B. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1267378 · Cited by 55
Delivery of a sebum modulator by an engineered skin microbe in mice
Knödlseder, N., Fábrega, M.-J., Santos‐Moreno, J., Manils, J., Toloza, L., Vilar, M. M., Fernández, C., Broadbent, K., Maruotti, J., Leménager, H., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-02072-4 · Cited by 42
Engineering commensal bacteria to rewire host–microbiome interactions
Hwang, I. Y., & Chang, M. W. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.09.007 · Cited by 41
Self-citationThe triple interactions between gut microbiota, mycobiota and host immunity
Yang, J., Yang, H., & Li, Y. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2094888 · Cited by 49
“It was found that this engineered strain has preventive and therapeutic effects against intestinal infections caused by P. aeruginosa (Hwang et al. 2017).”
BackgroundWadan, A.-H. S., El‐Aziz, M. K. A., & Ellakwa, D. E. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04155-2 · Cited by 61
“The complexity and cost of metagenomic sequencing and data interpretation may limit accessibility, particularly in low-resource settings (Hwang et al. 2017).”
Rapid screening of engineered microbial therapies in a 3D multicellular model
Harimoto, T., Singer, Z. S., Velazquez, O. S., Zhang, J. T., Castro, S., Hinchliffe, T. E., Mather, W., & Danino, T. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1820824116 · Cited by 44
Future trends in synthetic biology in Asia
Mao, N., Aggarwal, N., Poh, C. L., Cho, B., Kondo, A., Liu, C., Yew, W. S., & Chang, M. W. (2021) · Advanced Genetics · doi:10.1002/ggn2.10038 · Cited by 44
“It is envisioned that future smart medicine could come in the form of living cells that detect the diseased states and respond with therapeutic accuracy accordingly.(129) In other medical applications apart from therapeutics, synthetic”
BackgroundSelf-citationCulture-Delivery Live Probiotics Dressing for Accelerated Infected Wound Healing
Sun, Y., Liu, M., Tang, X., Zhou, Y., Zhang, J., & Yang, B. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c12845 · Cited by 40
Zainuddin, H. S., Bai, Y., & Mansell, T. J. (2019) · Engineering in Life Sciences · doi:10.1002/elsc.201900003 · Cited by 39
Stem Cell Impairment at the Host-Microbiota Interface in Colorectal Cancer
Marzano, M., Fosso, B., Piancone, E., Defazio, G., Pesole, G., & Robertis, M. D. (2021) · Cancers · doi:10.3390/cancers13050996 · Cited by 41
“Initial encouraging results in animal models have shown indeed that the engineered Escherichia coli Nissle 1917 expressing biofilm-disrupting enzyme is capable of counteracting Pseudomonas aeruginosa biofilm infection [159], an effect that has been demonstrated similarly by probiotic bacteria, Lactobacilli, against th…”
ResultWu, J., Huang, H., Wang, L., Gao, M., Meng, S., Zou, S., Feng, Y., Feng, Z., Zhu, Z., Cao, X., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2316575 · Cited by 41
Surface nanocoating of bacteria as a versatile platform to develop living therapeutics
Cao, Z., & Liu, J. (2024) · Nature Protocols · doi:10.1038/s41596-024-01019-6 · Cited by 40
Engineered 5-HT producing gut probiotic improves gastrointestinal motility and behavior disorder
Li, B., Li, M., Luo, Y., Li, R., Li, W., & Liu, Z. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1013952 · Cited by 49
“Owing to its excellent safety profile and genetic tractability, EcN has been modified as a versatile probiotic strain and proven to be effective for treating numerous diseases, including antitumor drug carriers, pathogens resistance, immunotherapy and metabolic abnormalities improvement (Hwang et al., 2017; Ho et al.,…”
BackgroundAdvanced probiotics: bioengineering and their therapeutic application
Parvin, T., & Sadras, S. R. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09309-8 · Cited by 42
“The probiotic can colonize the mouse intestine for around 3 weeks and reduced P. aeruginosa levels in the infected mouse model by 77% as compared to the control group [87].”
Engineering chemical interactions in microbial communities
Kenny, D. J., & Balskus, E. P. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00664k · Cited by 42
Engineering microbial diagnostics and therapeutics with smart control
Amrofell, M. B., Rottinghaus, A. G., & Moon, T. S. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.05.006 · Cited by 35
“Nearly all the therapeutic microbes described in this review rely solely on a single input, including a pathogen signaling molecule [18], an exogenous inducer [20], a self-produced quorum signal [21-23], or a biogeographical signal [29,30] to complete their therapeutic function.”
BackgroundDevelopment of Cell-Based Sentinels for Nitric Oxide: Ensuring Marker Expression and Unimodality
McKay, R., Hauk, P., Quan, D. N., & Bentley, W. E. (2018) · ACS Synthetic Biology · doi:10.1021/acssynbio.8b00146 · Cited by 35
“That is, investigations of engineered commensal bacteria for the purpose of monitoring and potentially modulating health have appeared and show promise.39–42 Hwang et al. (2017) relied on gavage addition of “smart” bacteria to mice instead of a capsule.”
BackgroundSelf-citationThe gut microbes in inflammatory bowel disease: Future novel target option for pharmacotherapy
Yuan, S., Wang, K.-S., Meng, H., Hou, X.-T., Xue, J.-C., Liu, B., Cheng, W., Li, J., Zhang, H., Nan, J., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114893 · Cited by 37
Tchesnokova, V. L., Larson, L., Basova, I., Sledneva, Y., Choudhury, D., Solyanik, T., Heng, J., Bonilla, T. C., Pham, S., Schartz, E. M., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00337-2 · Cited by 43
Synthetic bacterial therapies for intestinal diseases based on quorum-sensing circuits
Dang, Z., Gao, M., Wang, L., Wu, J., Guo, Y., Zhu, Z., Huang, H., & Kang, G. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108142 · Cited by 36
Phage lysins for intestinal microbiome modulation: current challenges and enabling techniques
Pottie, I., Vázquez, R., de Wiele, T. V., & Briers, Y. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2387144 · Cited by 38
“38 More recently, the same detection and expression system was used to express PA2-GNU7, a specific antimicrobial peptide, to eradicate P. aeruginosa .”
MethodAdvancing therapeutic applications of synthetic gene circuits
Higashikuni, Y., Chen, W. C. W., & Lu, T. K. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.06.011 · Cited by 36
“aeruginosa infection in both Caenorhabditis elegans and mouse models [54].”
BackgroundZhang, X., Feng, Z., Li, H., Yang, H., Li, L., Zhang, C., Dai, P., Wang, H., Xue, H., Wang, Y., et al. (2025) · Nature Microbiology · doi:10.1038/s41564-025-02057-w · Cited by 44
“Intestinal engineered microbes have shown potentiality in s ensing inflammatory biomarkers 3–5 and pathogens 6,7 ; treating inflammatory bowel disease 5,8 , cancers 9–11 and metabolic syndromes 12–14 ; killing pathogen microbes 7,15 ; and so on.”
Human Microbiome and Its Medical Applications
Zhang, Y., Zhou, L., Xia, J., Dong, C., & Luo, X. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.703585 · Cited by 32
Tracking of Engineered Bacteria In Vivo Using Nonstandard Amino Acid Incorporation
Praveschotinunt, P., Courchesne, N. D., den Hartog, I., Lu, C., Kim, J. J., Nguyen, P. Q., & Joshi, N. S. (2018) · ACS Synthetic Biology · doi:10.1021/acssynbio.8b00135 · Cited by 32
Engineered Living Biofilm with Enhanced Metal Binding Ability for Corrosion Protection in Seawater
Li, Z., Ren, Y., Li, Z., Zhang, J., Fan, Y., Jiang, G., Xu, D., Gu, T., & Wang, F. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202313120 · Cited by 31
Engineering bacteria for cancer therapy
Harimoto, T., & Danino, T. (2019) · Emerging Topics in Life Sciences · doi:10.1042/etls20190096 · Cited by 35
Engineering E. coli for Magnetic Control and the Spatial Localization of Functions
Aubry, M., Wang, W., Guyodo, Y., Delacou, E., Guigner, J., Espéli, O., Lebreton, A., Guyot, F., & Gueroui, Z. (2020) · ACS Synthetic Biology · doi:10.1021/acssynbio.0c00286 · Cited by 35
Huang, F., Lu, Y., & Liao, Y.-H. (2020) · Innate Immunity · doi:10.1177/1753425920959410 · Cited by 36
“aeruginosa gut infection in two animal models.(45) It supports the development of engineered probiotics to eliminate and prevent bacterial gut infections.”
BackgroundEngineering the Microbiome to Prevent Adverse Events: Challenges and Opportunities
Khan, S. M., Hauptman, R., & Kelly, L. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-031620-031509 · Cited by 32
Living Therapeutics: The Next Frontier of Precision Medicine
Kelly, V. W., Liang, B. K., & Sirk, S. J. (2020) · ACS Synthetic Biology · doi:10.1021/acssynbio.0c00444 · Cited by 30
Transcriptional programming in a Bacteroides consortium
Huang, B. D., Groseclose, T. M., & Wilson, C. J. (2022) · Nature Communications · doi:10.1038/s41467-022-31614-8 · Cited by 36
Engineering E. coli strains using antibiotic-resistance-gene-free plasmids
Amrofell, M. B., Rengarajan, S., Vo, S., Tovar, E. S. R., LoBello, L., Dantas, G. A., & Moon, T. S. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100669 · Cited by 42
Timmis, K. N., Timmis, K. N., Brüssow, H., & Fernández, L. Á. (2018) · Microbial Biotechnology · doi:10.1111/1751-7915.13355 · Cited by 29
“genic bacteria, and antibacterial products, such as microcins (Hwang et al., 2017) or toxins delivered by type 6 secretion systems (Alcoforado Diniz et al.”
BackgroundCarolak, E., Czajkowska, J., Stypułkowska, A., Waszczuk, W., Dutkiewicz, A., & Grzymajło, K. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2519696 · Cited by 41
Kim, S., Kerns, S. J., Ziesack, M., Bry, L., Gerber, G. K., Way, J. C., & Silver, P. A. (2018) · ACS Synthetic Biology · doi:10.1021/acssynbio.8b00271 · Cited by 34
“coli including artificial cell patterning, logic gates, synchronization, and population density regulation, they were mainly expressed in multi-copy plasmids optimal for in vitro settings only (Basu et al., 2005; Brenner et al., 2007; Hwang et al., 2016; Scott et al., 2017; Tabor et al., 2009; Tamsir et al., 2011).”
BackgroundA Synthetic System That Senses Candida albicans and Inhibits Virulence Factors
Tscherner, M., Giessen, T. W., Markey, L., Kumamoto, C. A., & Silver, P. A. (2019) · ACS Synthetic Biology · doi:10.1021/acssynbio.8b00457 · Cited by 33
Kojima, R., Aubel, D., & Fussenegger, M. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03486-y · Cited by 31
Triassi, A. J., Fields, B. D., Monahan, C. E., Means, J., Park, Y., Doosthosseini, H., Padmakumar, J. P., Isabella, V. M., & Voigt, C. A. (2023) · Cell Systems · doi:10.1016/j.cels.2023.05.004 · Cited by 32
Rutter, J. W., Ozdemir, T., Galimov, E. R., Quintaneiro, L. M., Rosa, L., Thomas, G. M. H., Cabreiro, F., & Barnes, C. P. (2019) · ACS Synthetic Biology · doi:10.1021/acssynbio.9b00166 · Cited by 29
Probiotic cultivated meat: bacterial-based scaffolds and products to improve cultivated meat
Kolodkin‐Gal, I., Dash, O., & Rak, R. (2023) · Trends in biotechnology · doi:10.1016/j.tibtech.2023.09.002 · Cited by 32
Li, H., Jia, M., Qi, Q., & Wang, Q. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.01829-23 · Cited by 33
“In response to the acyl-homoserine lactone produced by P. aeruginosa , engineered bacteria released the antibiofilm enzyme dispersin B to kill pathogenic bacteria (7).”
BackgroundSynthetic Biology-Driven Microbial Therapeutics for Disease Treatment
Kim, T. H., Cho, B., & Lee, D. (2024) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2407.07004 · Cited by 34
Sustainable therapies by engineered bacteria
Álvarez, B., & Fernández, L. Á. (2017) · Microbial Biotechnology · doi:10.1111/1751-7915.12778 · Cited by 32
“…example, EcN was engineered to produce bacteriocins and swim towards the pathogen in response to QS signals of Pseudomonas aeruginosa (Hwang et al., 2014), and the resulting construct shown to exhibit antimicrobial activity against this pathogen in the gut of mouse models (Hwang et al., 2017).”
BackgroundEncapsulin carrier proteins for enhanced expression of antimicrobial peptides
Lee, T. H., Carpenter, T. S., D’haeseleer, P., Savage, D. F., & Yung, M. C. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.27222 · Cited by 28
Convergence of Nanotechnology and Bacteriotherapy for Biomedical Applications
Liu, J., Yuan, S., Bremmer, A., & Hu, Q. (2024) · Advanced Science · doi:10.1002/advs.202309295 · Cited by 31
Assembly of functional microbial ecosystems: from molecular circuits to communities
Wu, S., Zhou, Y., Dai, L., Yang, A., & Qiao, J. (2024) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuae026 · Cited by 33
Understanding and Engineering Distributed Biochemical Pathways in Microbial Communities
Cao, X., Hamilton, J. J., & Venturelli, O. S. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b01006 · Cited by 36
Engineering Saccharomyces cerevisiae for medical applications
Maneira, C., Chamas, A., & Lackner, G. (2025) · Microbial Cell Factories · doi:10.1186/s12934-024-02625-5 · Cited by 35
“The advancements in the understanding of Sb’s genetic engineering and colonization patterns, as well as the success of LBP’s applications in other probiotic spe-cies—mostly E. coli Nissle 1917—opened the doors for the development of yeast-based LBPs in the last years [271–273].”
Combinatorial Sensor Design in Caulobacter crescentus for Selective Environmental Uranium Detection
Park, D. M., & Taffet, M. J. (2019) · ACS Synthetic Biology · doi:10.1021/acssynbio.8b00484 · Cited by 27
Advancements in gene editing technologies for probiotic-enabled disease therapy
Wang, L., Hu, J., Li, K., Zhao, Y., & Zhu, M. (2024) · iScience · doi:10.1016/j.isci.2024.110791 · Cited by 36
“146,147 EcN is the active component of microbial drug Mutaflor for the treatment of gastrointestinal disorders includingdiarrhea,diverticulardisease and ulcerative colitis.”
BackgroundSynthetic macromolecular switches for precision control of therapeutic cell functions
Teixeira, A. P., & Fussenegger, M. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00235-9 · Cited by 34
Ahghari, M. R., Ahghari, M. R., Kamalzare, M., & Maleki, A. R. (2022) · Scientific Reports · doi:10.1038/s41598-022-14501-6 · Cited by 25
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. Ø., & Sommer, M. O. A. (2022) · BMC Bioinformatics · doi:10.1186/s12859-022-05108-9 · Cited by 29
“coli Nissle 1917 has been used for many years in clinical settings and could prove to be a good chassis for advanced microbiome therapeutics in the future [11, 50, 56, 57, 58, 59, 60, 61].”
MethodKim, D., Kim, Y.-S., & Yoon, S. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042122 · Cited by 44
“It was engineered to sense and kill Pseudomonas aeruginosa in Caenorhabditis elegans and mouse infection models [5].”
BackgroundFermented Dairy Food Intake and Risk of Colorectal Cancer: A Systematic Review and Meta-Analysis
Liang, Z., Song, X., Hu, J., Wu, R., Li, P., Dong, Z., Liang, L., & Wang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.812679 · Cited by 26
“The case–control studies were conducted in five countries (Netherland, Moroccan, France, the United States, Canada).”
BackgroundInfluentialPrecision engineering of the probiotic Escherichia coli Nissle 1917 with prime editing
Chen, P.-R., Wei, Y., Li, X., Yu, H., Wang, S., Yuan, X.-Z., & Xia, P. (2025) · Applied and Environmental Microbiology · doi:10.1128/aem.00031-25 · Cited by 25
“EcN has been engineered to sense and eliminate pathogens (32, 33), convert dietary compounds into anti-cancer agents (34), and deliver immunotherapeutics in situ for the treatment of colorectal neoplasia (35), showcasing great potential for medical applications.”
Antimicrobial roles of probiotics: Molecular mechanisms and application prospects
Yu, X., Liu, Z., Liu, Y., Li, X., Wang, B., & Yin, J. (2025) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2025.105146 · Cited by 27
Engineering microbes for targeted strikes against human pathogens
Hwang, I. Y., Lee, H. L., Huang, J. G., Lim, Y. Y., Yew, W. S., Lee, Y. S., & Chang, M. W. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2827-7 · Cited by 25
Self-citation
Metadata
- Authors
- Hwang, I. Y., Koh, E., Wong, A., March, J. C., Bentley, W. E., Lee, Y. S., & Chang, M. W.
- Affiliations
- National University of Singapore (SG)
- Cornell University (US)
- University of Maryland, College Park (US)
- Corresponding author
- Chang, Matthew Wook
- ORCID
- Venue
- Nature Communications
- Published
- 2017-04-11
- Volume
- 8
- Issue
- 1
- Pages
- 15028-15028
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5394271
- OpenAlex
- W2605968366
- Cited by
- 472
- References
- 50
- Citations by year
- 2026: 44 · 2025: 53 · 2024: 51 · 2023: 55 · 2022: 68 · 2021: 44 · 2020: 54 · 2019: 53 · 2018: 41 · 2017: 9
- FWCI
- 31.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National University of Singapore (DPRT/943/09/14)
- National University Health System
- Defense Threat Reduction Agency (HDTRA1‐13‐0037, HDTRA1, DPRT/943/09/14)
- U.S. Air Force
- Medical Research Council
- National Medical Research Council (CBRG11nov109)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- engineered probiotics, Escherichia coli, Pseudomonas aeruginosa, intestinal infection, Escherichia coli Nissle 1917, prophylaxis, therapeutic activities, Caenorhabditis elegans, mouse model
- MeSH terms
- Microorganisms, Genetically-Modified, Animals, Disease Models, Animal, Escherichia coli, Female, Gastroenteritis, Genetic Engineering, Mice, Inbred ICR, Pseudomonas aeruginosa, Pseudomonas Infections, Virulence, Caenorhabditis elegans, Probiotics, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.